FAK inhibitor monotherapy has shown mixed clinical efficacy in mesothelioma tumours that harbour loss of specific tumour suppressive signals, such as Merlin (encoded by NF2 gene; 131, 132, 133). This evidence concerns the gene PTK2 and mesothelioma.